Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Peter Jenner, José-Francisco Rocha, Joaquim J Ferreira, Olivier Rascol & Patrício Soares-da-Silva. (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Review of Neurotherapeutics 21:9, pages 1019-1033.
Read now
Read now
Conor Chandler, Henri Folse, Peter Gal, Ameya Chavan, Irina Proskorovsky, Conrado Franco-Villalobos, Yunyang Wang & Alex Ward. (2021) Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study. Journal of Market Access & Health Policy 9:1.
Read now
Read now
Ryan N. Hansen, Kangho Suh, Michael Serbin, Chuck Yonan & Sean D. Sullivan. (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. Journal of Medical Economics 24:1, pages 563-569.
Read now
Read now
Sergio I. Prada, Ana Melissa Pérez, Jaime Valderrama–Chaparro, María Isabel Molina–Echeverry, Jorge Luis Orozco & Yuri Takeuchi. (2020) Direct cost of Parkinson’s disease in a health system with high judicialization: evidence from Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 20:6, pages 587-593.
Read now
Read now
Anil Gumber, Bhanu Ramaswamy & Oranuch Thongchundee. (2019) Effects of Parkinson’s on employment, cost of care, and quality of life of people with condition and family caregivers in the UK: a systematic literature review. Patient Related Outcome Measures 10, pages 321-333.
Read now
Read now
Julia Lowin, Kavita Sail, Rakhi Baj, Yash J. Jalundhwala, Thomas S. Marshall, Henrietta Konwea & K. R. Chaudhuri. (2017) The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. Journal of Medical Economics 20:11, pages 1207-1215.
Read now
Read now
Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín. (2015) Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 889-911.
Read now
Read now
Evelyn Walter & Per Odin. (2015) Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. Journal of Medical Economics 18:2, pages 155-165.
Read now
Read now
Julia Lowin, Annika Bergman, K. Ray Chaudhuri, Leslie J. Findley, Claudia Roeder, Mathias Schifflers, Eifiona Wood & Stephen Morris. (2011) A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. Journal of Medical Economics 14:5, pages 584-593.
Read now
Read now
Articles from other publishers (36)
Sara Abidar, Lucian Hritcu & Mohamed Nhiri. (2023) The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine-
Induced Parkinson’s Disease in Zebrafish: The Current
Applications and Perspectives. CNS & Neurological Disorders - Drug Targets 22:10, pages 1472-1483.
Crossref
Crossref
M. T. Pellecchia, M. Picillo, M. C. Russillo, V. Andreozzi, C. Oliveros & C. Cattaneo. (2023) The effects of safinamide according to gender in Chinese parkinsonian patients. Scientific Reports 13:1.
Crossref
Crossref
Bonn Lee, Charlotte Edling, Shiraz Ahmad, Fiona E. N. LeBeau, Gary Tse & Kamalan Jeevaratnam. (2023) Clinical and Non-Clinical Cardiovascular Disease Associated Pathologies in Parkinson’s Disease. International Journal of Molecular Sciences 24:16, pages 12601.
Crossref
Crossref
Sonia Raj, Rekha Sarvankar, Luís Filipe, Valerio Benedetto, Nicola Mason, Jennifer Dawber, James Hill & Andrew Clegg. (2023) Cost-effectiveness of levodopa-carbidopa intestinal gel in treating people with advanced Parkinson's disease. British Journal of Neuroscience Nursing 19:4, pages 140-144.
Crossref
Crossref
Idaira Rodríguez‐Santana, Tiago Mestre, Ferdinando Squitieri, Rosa Willock, Astri Arnesen, Alison Clarke, Barbara D'Alessio, Alex Fisher, Rebecca Fuller, Jamie L. Hamilton, Hayley Hubberstey, Cath Stanley, Louise Vetter, Michaela Winkelmann, Maria Doherty, Yunchou Wu, Alan Finnegan & Samuel Frank. (2022) Economic burden of Huntington disease in Europe and the USA: Results from the Huntington's Disease Burden of Illness study. European Journal of Neurology 30:4, pages 1109-1117.
Crossref
Crossref
Klas Kellerborg, Jenny M. Norlin & Per Odin. (2022)
The Relationship between
PDQ
‐8 and Costs in Parkinson's Disease—A Swedish Register‐Based Study
. Movement Disorders Clinical Practice 10:2, pages 231-237.
Crossref
Crossref
Jenny Norlin, Frida Hjalte, Christopher Kruse, Richard Dodel, Kristina Rosqvist & Per Odin. (2022) Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study. Acta Neurologica Scandinavica 145:6, pages 743-752.
Crossref
Crossref
K. Ray Chaudhuri, A. Simon Pickard, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Yanjun Bao, Julia Sus, Glynn Jones, Christian Ridley, Julia Oddsdottir, Seyavash Najle-Rahim, Matthew Madin-Warburton, Weiwei Xu & Anette Schrag. (2022) The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England. PharmacoEconomics 40:5, pages 559-574.
Crossref
Crossref
Emily Ming Li Soh, Shermyn Neo, Seyed Ehsan Saffari, Aidan Sheng Yong Wong, Ganga Ganesan, Wei Li, Hwee Lan Ng, Zheyu Xu, Kay Yaw Tay, Wing Lok Au, Kelvin Bryan Tan & Louis Chew Seng Tan. (2022) Longitudinal Healthcare Utilization and Costs in Parkinson’s Disease: Pre-Diagnosis to 9 Years After. Journal of Parkinson's Disease 12:3, pages 957-966.
Crossref
Crossref
Christine Schofield, K Ray Chaudhuri, Camille Carroll, Jagdish C Sharma, Nicola Pavese, Jonathan Evans, Thomas Foltynie, Heinz Reichmann, Laura Zurowska, Patrício Soares-da-Silva & Andrew Lees. (2022) Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative Disease Management 12:2, pages 77-91.
Crossref
Crossref
Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J. Soileau, Ramon Rodriguez-Cruz, Stuart H. Isaacson, Aristide Merola, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Juan Carlos Parra, Pavnit K. Kukreja, Koray Onuk, Lars Bergmann, James Pike & K. Ray Chaudhuri. (2022) Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy 11:1, pages 303-318.
Crossref
Crossref
Sarah Scobie, Sue Jowett, Tosin Lambe, Smitaa Patel, Rebecca Woolley, Natalie Ives, Caroline Rick, Christina Smith, Marion C Brady, Carl Clarke & Cath Sackley. (2021) Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial. Pilot and Feasibility Studies 7:1.
Crossref
Crossref
Frida Hjalte, Jenny M. Norlin, Klas Kellerborg & Per Odin. (2021) Parkinson’s disease in Sweden—resource use and costs by severity. Acta Neurologica Scandinavica 144:5, pages 592-599.
Crossref
Crossref
Erik Krause, Jaskaren Randhawa & Raja Mehanna. (2021) Comparing subjective and objective response to medications in Parkinson's disease patients using the Personal KinetiGraph™. Parkinsonism & Related Disorders 87, pages 105-110.
Crossref
Crossref
Christopher Kruse, Sabrina Kretschmer, Anna Lipinski, Malte Verheyen, David Mengel, Monika Balzer-Geldsetzer, Stefan Lorenzl, Carmen Richinger, Christian Schmotz, Lars Tönges, Dirk Woitalla, Stephan Klebe, Anette Schrag & Richard Dodel. (2021) Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study. PharmacoEconomics 39:5, pages 601-615.
Crossref
Crossref
Katarzyna Smilowska, Daniel J. van Wamelen, Tomasz Pietrzykowski, Alexander Calvano, Carmen Rodriguez-Blazquez, Pablo Martinez-Martin, Per Odin & K. Ray Chaudhuri. (2021) Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review. Journal of Parkinson's Disease 11:2, pages 475-489.
Crossref
Crossref
Stuart H Isaacson, Kelly E Lyons, Fahd Amjad & Rajesh Pahwa. (2021) Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease. Neurology 17:1, pages 36.
Crossref
Crossref
Irina A. Denisova, Tatiana V. Chubarova, Irina E. Bogatova, Sergei A. Vartanov, Valerian G. Kucheryanu, Viсtor M. Polterovich, Natalia A. Turdyeva & Marina V. Shakleina. (2020) Estimating economic efficiency of preclinical diagnostics of Parkinson's disease with cost-utility approach. Population and Economics 4:3, pages 111-127.
Crossref
Crossref
Rajesh Pahwa, Filip Bergquist, Malcolm Horne & Michael E. Minshall. (2020) Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph®. Journal of Clinical Movement Disorders 7:1.
Crossref
Crossref
Jing Han Ng, Angela An Qi See, Zheyu Xu & Nicolas Kon Kam King. (2020) Longitudinal medication profile and cost savings in Parkinson’s disease patients after bilateral subthalamic nucleus deep brain stimulation. Journal of Neurology 267:8, pages 2443-2454.
Crossref
Crossref
Mario PradoJrJr & Roland Dominic Jamora. (2020) Cost of Parkinson’s disease among Filipino patients seen at a public tertiary hospital in Metro Manila. Journal of Clinical Neuroscience 74, pages 41-46.
Crossref
Crossref
Carlo Cattaneo, Wolfgang H. Jost & Erminio Bonizzoni. (2020) Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients. Journal of Parkinson's Disease 10:1, pages 89-97.
Crossref
Crossref
Joy Read, Sarah Cable, Charlotte Löfqvist, Susanne Iwarsson, Gergely Bartl & Anette Schrag. (2019) Experiences of health services and unmet care needs of people with late-stage Parkinson’s in England: A qualitative study. PLOS ONE 14:12, pages e0226916.
Crossref
Crossref
Nafsika Afentou, Johan Jarl, Ulf‐G Gerdtham & Sanjib Saha. (2019) Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review. Movement Disorders Clinical Practice 6:4, pages 282-290.
Crossref
Crossref
Monika Balzer-Geldsetzer, Joaquim Ferreira, Per Odin, Bastiaan R. Bloem, Wassilios G. Meissner, Stefan Lorenzl, Michael Wittenberg, Richard Dodel & Anette Schrag. (2018) Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology 18:1.
Crossref
Crossref
Chun-Shuo Shan, Hong-Feng Zhang, Qing-Qing Xu, Yi-Hua Shi, Yong Wang, Yan Li, Yan Lin & Guo-Qing Zheng. (2018) Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials. Frontiers in Aging Neuroscience 10.
Crossref
Crossref
Ines Banjari, Tihana Marček, Svetlana Tomić & Viduranga Y. Waisundara. (2018) Forestalling the Epidemics of Parkinson's Disease Through Plant-Based Remedies. Frontiers in Nutrition 5.
Crossref
Crossref
Laura Kay, Ilse S. Pienaar, Ruwini Cooray, Gary Black & Meera Soundararajan. (2018) Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders. Molecular Neurobiology 55:9, pages 7352-7365.
Crossref
Crossref
Sharada Weir, Mihail Samnaliev, Tzu‐Chun Kuo, Travis S. Tierney, Silke Walleser Autiero, Rod S. Taylor & Anette Schrag. (2018) Short‐ and long‐term cost and utilization of health care resources in Parkinson's disease in the UK. Movement Disorders 33:6, pages 974-981.
Crossref
Crossref
Freya DiederichHans-Helmut KönigClaudia MietznerChristian Brettschneider. (2018) Costs of informal nursing care for patients with neurologic disorders. Neurology 90:1, pages 28-34.
Crossref
Crossref
Jun-Xiu Yang & Lei Chen. (2017) Economic Burden Analysis of Parkinson’s Disease Patients in China. Parkinson's Disease 2017, pages 1-7.
Crossref
Crossref
Luca Degli Esposti, Carlo Piccinni, Diego Sangiorgi, Flavio Nobili & Stefano Buda. (2015) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurological Sciences 37:2, pages 227-234.
Crossref
Crossref
Gertrúd Tamás, László Gulácsi, Dániel Bereczki, Petra Baji, Annamária Takáts, Valentin Brodszky & Márta Péntek. (2014) Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE 9:9, pages e107704.
Crossref
Crossref
Joseph JankovicConnie Marras. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment
7
22
.
Paola Giunti, Julia Greenfield, Alison J Stevenson, Michael H Parkinson, Jodie L Hartmann, Ruediger Sandtmann, James Piercy, Jamie O?Hara, Leo Ruiz Casas & Fiona M Smith. (2013) Impact of Friedreich?s Ataxia on health-care resource utilization in the United Kingdom and Germany. Orphanet Journal of Rare Diseases 8:1, pages 38.
Crossref
Crossref
Nad?ge Costa, Laura Ferlicoq, H?l?ne Derumeaux-Burel, Thomas Rapp, Val?rie Garnault, Sophie Gillette-Guyonnet, Sandrine Andrieu, Bruno Vellas, Michel Lamure, Alain Grand & Laurent Molinier. (2013) Comparison of Informal Care Time and Costs in Different Age-Related Dementias: A Review. BioMed Research International 2013, pages 1-15.
Crossref
Crossref